US › Healthcare

Nuvalent Inc (NUVL)

US · Healthcare · Biotechnology

$123.960.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-109.3M
Profit YoY
-29.2%
EPS
$-1.39
EPS estimate
$-1.31

EPS came in at -1.39 against a street estimate of -1.31 — a miss of 6.1%.

Key statistics

Market cap
$9.81B
Forward P/E
0.0
P/B
8.35
Book value
$14.89
EPS (TTM)
$-6.06
52-week high
$123.99
52-week low
$71.13
50-day MA
$112.22
200-day MA
$103.43
Beta
1.14

Analyst view

Analysts rate Nuvalent Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $124.00.

Shareholding

Insiders
2.78%
Institutions
113.30%

Largest institutional holders

FundStake
Deerfield Management Co21.80%
FMR Inc11.72%
Paradigm Biocapital Advisors LP6.73%
Vanguard Group Inc6.63%
BlackRock Inc6.10%
JPMorgan Chase & Co3.90%
RA Capital Management, LLC3.20%
Vanguard Portfolio Management, LLC3.16%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nuvalent Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.